(Shanghai) U.S.-China Collaborations in Inflammatory Bowel Disease Research

All day


Progress -cooperation-a win-win situation


2013 Shanghai – Chicago Inflammatory Bowel Disease Forum


The inaugural ceremony of the Shanghai Inflammatory Bowel Disease Research Center



(Text and photos by Jun Shen)

Inflammatory bowel disease (IBD) is an emerging health problem in China, with a significantly increased incidence and prevalence over the last five years. The factors influencing the progression of IBD are likely multifactorial and provide an opportunity to study the epidemiologic, epigenetic and genetic aspects of IBD in an emerging population.

The University of Chicago has an extensive history in epidemiologic, epigenetic and genetic research in IBD. In addition, the University of Chicago IBD Center has a prominent reputation as a world leader in clinical research and clinical care. Renji Hospital, located in Shanghai and established in 1844, is one of the oldest hospitals built in China. The Department of Gastroenterology accepted over 1,800 hospitalizations of IBD in the past decade and the number of IBD outpatients reaches over 80 per week. In the late June, 2013, the 2013 Shanghai – Chicago Inflammatory bowel disease forum and the inauguration of the Shanghai IBD Research Center were held at Shanghai Renji Hospital. More than 350 officers, directors, doctors, vendors and staffs participated in this forum.

In this forum, the University of Chicago faculty recognizes the value in partnering with the Shanghai Renji Hospital and the Shanghai IBD Research Center to study IBD in an emerging population. In turn, Shanghai Renji Hospital and the Shanghai IBD Research Center recognize the significant expertise the University of Chicago IBD Center brings to the establishment of IBD clinical care and clinical, translational, epidemiologic and basic science research initiatives.

As the continuation of previous memorandum of cooperation, in this forum, the blueprint for cooperation has been discussed in detail. Prof. Stephen B. Hanauer (Chief, Section of Gastroenterology and Nutrition, the University of Chicago IBD Center) and Prof. Zhihua Ran (Director, Shanghai IBD Research Center) are the leaders of the cooperative program. Through this partnership, the University of Chicago IBD Center and the Shanghai IBD Center/ the Shanghai Renji Hospital will enter cooperation regarding the 1) exchange of medical residents/fellows as clinical observers, 2) exchange of gastroenterology faculty as clinical observers, 3) establishment of an infrastructure for cooperative clinical, translational, epidemiologic and general IBD research, 4) establishment of guidelines for exchange of research material and information and 5) the development and initiation of joint research initiatives.

2013年6月29日June 29th 2013 Agenda(以当天安排为准)

08:00    开幕式

08:05    冉志华   中华医学会消化病学分会炎症性肠病学组领导致辞

08:10    胡品津   医院领导致辞

08:15    孔宪明   卫生局领导致辞

08:20    徐建光   上海市炎症性肠病中心揭牌仪式

Section 1     世界范围内炎症性肠病的争议与挑  Worldwide View of Controversies and Challenges in IBD

08:30    Stephen B. Hanauer :  New Advances in the Therapy of IBD

09:00    Simon Travis:  The 2013 ECCO Consensus on Ulcerative Colitis: the Unanswered Questions

09:30    冉志华 : Prospective View of Paris Definition for Disease-modification Trials

10:00    Discussion    讨论

10:15    Coffee Break    茶歇

Section 2     炎症性肠病基础和临床的顶层设计 Top-level Design of Basic and Clinical View in IBD

10:30    Russell D. Cohen: State of the Art Treatment For Crohn’s Disease

10:50    Eugene B. Chang:  Microbiome and IBD: What we have learned and what is in the future

11:10    John H. Kwon: Current and Future Diagnostic Modulation for IBD

11:30   吴开春 : A Variety of Assessment Methods and the Time Points of the Effectiveness of Biologic Agents

11:50    Discussion    讨论

12:10    Lunch    午餐

Section 3     炎症性肠病的难点和前瞻    Difficulties and Prospects of IBD

14:00     周峰: 基因易感性和炎症性肠病疾病表型的相关性

             Correlations between Genetic Susceptibility and Phenotypes in IBD

14:20    钱家鸣: IBD孕妇用药的起点、终点和选择

Medication in IBD Pregnancy: When to Start, When to Stop and What to Choose

14:40    陈旻湖: 炎症性肠病患者的预防接种

             Vaccination in IBD

15:00   吴建新: 儿童与青少年IBD的流行趋势与挑战

             Inflammatory Bowel Disease in Children and Adolescences: Trends and Challenges

15:20    讨论    Discussion

15:35    茶歇    Coffee Break

Section 4    炎症性肠病学术争鸣   Academic Debates

15:50     钟捷:轻中度IBD患者病初生物制剂治疗的循证依据和优势

                 Evidence and Advance of Biologic Agents Management in Mild to Moderate IBD Patients

16:10     吴小平:轻中度IBD患者升阶梯治疗的循证依据和获益

Evidence and Benefits of “Step-up” Management in Mild to Moderate IBD Patients

16:30     提问和回答    Questions and Answers

16:45    韩英:总结    Summary

16:50    胡仁伟:5-ASA口服和局部制剂在全结肠炎中联合使用的必要性和获益

              Necessity and Benefits of Combination 5-ASA Oral and Topical Preparations in Pancolitis Patients

17:10    高翔:全结肠炎及重度溃疡性结肠炎跳过5-ASA治疗的循证支持

             Evidence-based Support of “Skip”5-ASAs in Pancolitis or Several UC

17:30     提问和回答    Questions and Answers

17:45    刘玉兰:总结    Summary

17:50    冉志华:闭幕式    Closing Ceremony


Organizers: Jun Shen (Department of Medicine), John Kwon (Department of Medicine), and Russell Cohen (Inflammatory Bowel Disease Center) in collaboration with Shanghai Jiao-Tong University, Shanghai Institute of Digestive Disease, Ministry of Health, and Shanghai Medical Association.